ISX9 CPC
Alternative Names: ISX9-CPC; ISX9-CPC-IPS HeartLatest Information Update: 19 Jul 2023
Price :
$50 *
At a glance
- Originator IPS HEART
- Class Isoxazoles; Stem cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cardiomyopathies; Duchenne muscular dystrophy; Heart failure
Most Recent Events
- 06 Jul 2023 US FDA grants Rare Paediatric Drug designation for ISX9 CPC for treatment of cardiomyopathy associated with Danon disease
- 13 Apr 2023 US FDA grants Rare Paediatric Drug designation for ISX9 CPC for Duchenne muscular dystrophy
- 27 Feb 2023 IPS HEART plans to submit IND application for ISX9 CPC in US (IPS Heart pipeline, February 2023 )